Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
dc.citation.volume | 19 | |
dc.contributor.author | Brachat, Arndt H. | |
dc.contributor.author | Grom, Alexei A. | |
dc.contributor.author | Wulffraat, Nico | |
dc.contributor.author | Brunner, Hermine I. | |
dc.contributor.author | Quartier, Pierre | |
dc.contributor.author | Brik, Riva | |
dc.contributor.author | McCann, Liza | |
dc.contributor.author | Ozdogan, Huri | |
dc.contributor.author | Rutkowska-Sak, Lidia | |
dc.contributor.author | Schneider, Rayfel | |
dc.contributor.author | Gerloni, Valeria | |
dc.contributor.author | Harel, Liora | |
dc.contributor.author | Terreri, Maria [UNIFESP] | |
dc.contributor.author | Houghton, Kristin | |
dc.contributor.author | Joos, Rik | |
dc.contributor.author | Kingsbury, Daniel | |
dc.contributor.author | Lopez-Benitez, Jorge M. | |
dc.contributor.author | Bek, Stephan | |
dc.contributor.author | Schumacher, Martin | |
dc.contributor.author | Valentin, Marie-Anne | |
dc.contributor.author | Gram, Hermann | |
dc.contributor.author | Abrams, Ken | |
dc.contributor.author | Martini, Alberto | |
dc.contributor.author | Lovell, Daniel J. | |
dc.contributor.author | Nirmala, Nanguneri R. | |
dc.contributor.author | Ruperto, Nicolino | |
dc.coverage | London | |
dc.date.accessioned | 2020-07-17T14:03:13Z | |
dc.date.available | 2020-07-17T14:03:13Z | |
dc.date.issued | 2017 | |
dc.description.abstract | Background: Canakinumab is a human anti-interleukin-1 beta (IL-1 beta) monoclonal antibody neutralizing IL-1 beta-mediated pathways. We sought to characterize the molecular response to canakinumab and evaluate potential markers of response using samples from two pivotal trials in systemic juvenile idiopathic arthritis (SJIA). Methods: Gene expression was measured in patients with febrile SJIA and in matched healthy controls by Affymetrix DNA microarrays. Transcriptional response was assessed by gene expression changes from baseline to day 3 using adapted JIA American College of Rheumatology (aACR) response criteria (50 aACR JIA). Changes in pro-inflammatory cytokines IL-6 and IL-18 were assessed up to day 197. Results: Microarray analysis identified 984 probe sets differentially expressed (>= 2-fold difference | en |
dc.description.abstract | P < 0.05) in patients versus controls. Over 50% of patients with >= 50 aACR JIA were recognizable by baseline expression values. Analysis of gene expression profiles from patients achieving = 50 aACR JIA response at day 15 identified 102 probe sets differentially expressed upon treatment (>= 2-fold difference | en |
dc.description.abstract | P < 0.05) on day 3 versus baseline, including IL-1 beta, IL-1 receptors (IL1-R1 and IL1-R2), IL-1 receptor accessory protein (IL1-RAP), and IL-6. The strongest clinical response was observed in patients with higher baseline expression of dysregulated genes and a strong transcriptional response on day 3. IL-6 declined by day 3 (>= 8-fold decline | en |
dc.description.abstract | P < 0.0001) and remained suppressed. IL-18 declined on day 57 (>= 1.5-fold decline, P <= 0.002). Conclusions: Treatment with canakinumab in SJIA patients resulted in downregulation of innate immune response genes and reductions in IL-6 and clinical symptoms. Additional research is needed to investigate potential differences in the disease mechanisms in patients with heterogeneous gene transcription profiles. | en |
dc.description.affiliation | Norvartis Inst Biomed Res, Basel, Switzerland | |
dc.description.affiliation | PRCSG, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA | |
dc.description.affiliation | Wilhelmina Childrens Hosp, Dept Pediat Immunol & Rheumatol, Utrecht, Netherlands | |
dc.description.affiliation | Univ Paris 05, Unite Immunol Hematol & Rhumatol Pediat, Hop Necker Enfants Malad, Ctr Reference Natl Arthrit Juveniles,IMAGINE Inst, Paris, France | |
dc.description.affiliation | Rambam Med Ctr, Dept Pediat B, Haifa, Israel | |
dc.description.affiliation | Alder Hey Childrens NHS Fdn Trust, Liverpool, Merseyside, England | |
dc.description.affiliation | Cerrahpasa Tip Fak, Ic Hastaliklari ABD, Romatol BD, Istanbul, Turkey | |
dc.description.affiliation | Inst Rheumatol, Paediat Clin, Warsaw, Poland | |
dc.description.affiliation | Hosp Sick Children, Div Rheumatol, Toronto, ON, Canada | |
dc.description.affiliation | Ist Gaetano Pini, Div Reumatol, Milan, Italy | |
dc.description.affiliation | Schneider Childrens Med Ctr, Pediat Rheumatol Unit, Petah Tiqwa, Israel | |
dc.description.affiliation | Univ Fed Sao Paulo, Pediat, Sao Paulo, Brazil | |
dc.description.affiliation | British Columbia Childrens Hosp, Vancouver, BC, Canada | |
dc.description.affiliation | Univ Ziekenhuis Gent, Ctr Kinderreumatol, Ghent, Belgium | |
dc.description.affiliation | Randall Children’s Hospital at Legacy Emanuel, Portland, OR, USA | |
dc.description.affiliation | Floating Hosp Children, Rheumatol NEMC 286, Boston, MA USA | |
dc.description.affiliation | Novartis Pharmaceut, E Hanover, NJ USA | |
dc.description.affiliation | Univ Genoa, Genoa, Italy | |
dc.description.affiliation | Pediat II PRINTO, Ist Giannina Gaslini, Genoa, Italy | |
dc.description.affiliation | Novartis Inst Biomed Res, Cambridge, MA USA | |
dc.description.affiliationUnifesp | Univ Fed Sao Paulo, Pediat, Sao Paulo, Brazil | |
dc.description.source | Web of Science | |
dc.description.sponsorship | Novartis Pharma | |
dc.format.extent | - | |
dc.identifier | http://dx.doi.org/10.1186/s13075-016-1212-x | |
dc.identifier.citation | Arthritis Research & Therapy. London, v. 19, p. -, 2017. | |
dc.identifier.doi | 10.1186/s13075-016-1212-x | |
dc.identifier.file | WOS000396272700003.pdf | |
dc.identifier.issn | 1478-6354 | |
dc.identifier.uri | https://repositorio.unifesp.br/handle/11600/55236 | |
dc.identifier.wos | WOS:000396272700003 | |
dc.language.iso | eng | |
dc.publisher | Biomed Central Ltd | |
dc.relation.ispartof | Arthritis Research & Therapy | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Biomarkers | en |
dc.subject | Canakinumab | en |
dc.subject | Gene expression | en |
dc.subject | Interleukin-1 beta | en |
dc.subject | Juvenile idiopathic arthritis | en |
dc.subject | SJIA | en |
dc.title | Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy | en |
dc.type | info:eu-repo/semantics/article |
Arquivos
Pacote Original
1 - 1 de 1
Carregando...
- Nome:
- WOS000396272700003.pdf
- Tamanho:
- 4.78 MB
- Formato:
- Adobe Portable Document Format
- Descrição: